Share via:
The competition to develop the next blockbuster weight loss drug is heating up, and Pfizer is looking to make a big splash with its own entry.
On Tuesday, Pfizer presented the latest trial data on its ultra-long-acting GLP-1 experimental drug, code-named PF’3944. People taking PF’3944 lost significantly more weight than those on a placebo, the trial showed, even after switching to a monthly schedule. The company will push forward several Phase III trials of the drug this year.
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
The competition to develop the next blockbuster weight loss drug is heating up, and Pfizer is looking to make a big splash with its own entry.
On Tuesday, Pfizer presented the latest trial data on its ultra-long-acting GLP-1 experimental drug, code-named PF’3944. People taking PF’3944 lost significantly more weight than those on a placebo, the trial showed, even after switching to a monthly schedule. The company will push forward several Phase III trials of the drug this year.
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi
